Patent: 8,981,064

Summary for Patent: 8,981,064

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/459,743
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 8981064, titled "Therapeutic molecules that comprise sugars as therapeutic moieties," was granted to Emmanuelle Charon, a researcher from Aisin Seiki Co., Ltd., in 2015. The patent focuses on the therapeutic potential of molecules containing sugars as therapeutic moieties, highlighting their ability to target specific pathways involved in diseases. Background and Scope The patent delves into the concept of glycoscience, emphasizing the importance of carbohydrates in various biological processes. It highlights the fact that simple or complex sugars can be employed to develop therapeutic molecules, exhibiting specific properties that enable them to interact effectively with cellular receptors. By focusing on the therapeutic applications of sugar-based molecules, the patent offers a comprehensive approach to understanding their potential in treating various diseases. Claims and Disclosures The patent primarily makes two main claims: Molecules containing sugar moieties: The patent describes molecules comprising one or more sugar moieties as the therapeutic moieties, which can help treat various conditions, including but not limited to, inflammation, pain, and infection. These molecules can be used to target specific receptors or enzymes involved in disease progression. Methods for identifying target pathways: The patent also discloses novel methods for identifying target pathways involved in specific diseases using sugar-containing molecules. By employing various techniques such as immunoassays and bioanalytical methods, the patent provides a framework for the discovery of therapeutic applications based on glycoscience. The patent covers diverse categories of sugar-containing molecules, such as alpha-Gal, mannose, and lactose, among others. It discusses the importance of understanding the structures and properties of these sugar-containing molecules to optimize their therapeutic effectiveness. Key Points and Implications The patent highlights the benefits of sugar-based therapeutic molecules in addressing a range of diseases. It introduces the concept of glycoscience as a novel approach to the identification and development of therapeutic molecules. The patent offers a detailed framework for understanding the properties and therapeutic applications of sugar-containing molecules. It provides a solid foundation for potential applications of glycoscience in various fields, from bioengineering to medicine. Future Considerations The scope and claims of United States Patent 8981064 offer a forward-thinking perspective on the emerging field of glycoscience. The development and exploration of sugar-containing molecules with therapeutic potential hold significant promise for the creation of novel and innovative treatments for various diseases. However, the inherent complexity of glycoscience demands further study to fully understand and explore its vast therapeutic applications.

Details for Patent 8,981,064

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015		2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016		2027-08-23

International Patent Family for US Patent 8,981,064

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558
United States of America	9920134
United States of America	9493576
United States of America	9056915
United States of America	9045547